AbbVie Inc. / Syndesi Therapeutics SA

Cognitive impairment in Alzheimer's disease, MDD, and neurodegenerative disorders (SV2A modulation)

6.7M US cases/yr · $20.0B Global Alzheimer's disease market forecast (2030) · 1000 Total AbbVie-Syndesi acquisition value (USD MM, $130M upfront + $870M milestones)

Disease Overview

Cognitive impairment is a high-prevalence and high-unmet-need symptom domain spanning multiple neurological and psychiatric indications. Alzheimer's disease affects approximately 6.7 million US adults aged 65+ (Alzheimer's Association 2024), with an additional 12-18 million carrying mild cognitive impairment that often progresses. Major depressive disorder affects approximately 21 million US adults annually (NIMH/NSDUH), of whom an estimated 30-50% experience cognitive symptoms (deficits in attention, working memory and executive function) that are inadequately addressed by serotonergic antidepressants and persist into remission. Other neurodegenerative cognitive populations: Parkinson's disease dementia (~1 million US patients), Lewy body dementia (~1.4 million), and post-stroke or traumatic brain injury cognitive sequelae. SV2A (synaptic vesicle protein 2A) is the molecular target of levetiracetam (Keppra) in epilepsy and has emerged as a synaptic-density modulation target relevant to cognition. Syndesi's SV2A modulators (lead asset SDI-118) bind a distinct allosteric site from levetiracetam to enhance synaptic vesicle release without anticonvulsant activity, positioning SDI-118 as a potential pro-cognitive disease-modifying or symptomatic agent. Global Alzheimer's market was approximately $7B in 2023 and is forecast to reach $20B+ by 2030 with the launch of Leqembi and Kisunla; the broader cognitive impairment market across MDD and neurodegenerative disease is multiple times larger.

Competitive Landscape

Cognitive impairment in Alzheimer's and MDD is one of the most attempted and most heavily failed therapeutic areas in pharma; the SV2A modulation thesis represents one of the few viable mechanism-of-action paths beyond amyloid and tau. Approved Alzheimer's disease therapies: Aricept (donepezil, generic acetylcholinesterase inhibitor), Namenda (memantine, generic NMDA antagonist), Exelon (rivastigmine, generic) and Razadyne (galantamine, generic) provide modest symptomatic benefit; the new disease-modifying anti-amyloid antibodies are Aduhelm (aducanumab, Biogen, withdrawn 2024), Leqembi (lecanemab, Eisai/Biogen, ~$200M 2023 launch) and Kisunla (donanemab, Eli Lilly, FDA-approved July 2024). Tau-targeting and other AD pipeline: bepranemab (UCB/Roche), E2814 (Eisai), JNJ-63733657 (J&J), and small-molecule tau aggregation inhibitors. Cognition-focused pipeline: Cassava's simufilam (Phase 3, controversial), Anavex 2-73 (Anavex), Avadel's Lumryz, COR388 (Cortexyme, discontinued), and BIIB080 (Biogen tau ASO). MDD cognition-targeted: Auvelity (dextromethorphan/bupropion, Axsome), Trintellix (vortioxetine, Lundbeck/Takeda, with cognition labeling), and Spravato (esketamine, J&J). SV2A class precedent: Keppra (levetiracetam, UCB, generic) and Briviact (brivaracetam, UCB, second-generation SV2A) are the established epilepsy entrants; SDI-118's allosteric binding site differentiates it pharmacologically. Syndesi was spun out of UCB in 2017 with Novo Holdings backing; AbbVie's neuroscience strategy under the Allergan integration centers on AD, MDD, schizophrenia (Vraylar) and Parkinson's, making SDI-118 a strategic mechanism-of-action add adjacent to its existing antipsychotic and antidepressant franchises.